Over the past couple of decades, the mammalian target of rapamycin (mTOR) pathway has garnered immense popularity in terms of regulating various biological processes that are imperative for aging, cellular life, etc. Moreover, the impaired activity of mTOR complexes, especially mTORCI overactivation, has been largely involved in a range of age-related issues such as human renal diseases. Over the past three to four decades, advancements in assessing mTOR participants in renal pathological and physiological mechanisms have witnessed a considerable growth due to the notable rise in preclinical research within animal models by using genetic modification techniques of various mTOR components.
In recent years, phosphatidylinositol-3-kinase (PI3K)/AKT or mTOR signaling has emerged as one of the most critical intercellular pathways that is considered as a master regulator for cancer. Moreover, players involved in the current mTOR inhibitors market landscape are taking tremendous efforts toward the development of new drugs that primarily target P13K signaling. In recent years, owing to research and development, a number of mTOR inhibitors has been developed to combat cancer worldwide, and the trend is set to continue during the forecast period. Market players involved in the current mTOR inhibitors market are increasingly focusing on attaining approval from regulatory bodies for the recently developed mTOR inhibitors.
The development of P13K inhibitors is expected to play a key role in the treatment of cancer. Researchers and scientists are of the opinion that P13K inhibitor is one of the key therapeutic targets in the treatment of cancer– a trend that could gain further momentum over the course of the forecast period. In recent years, noteworthy efforts have been made toward the development of drugs that target P13K signaling; of this, a number of P13K targeted therapies are in clinical trials. Several mTOR inhibitors, such as NVP BEZ235 are currently in the phase one and two of clinical trials and awaiting approval from regulatory bodies. The increasing potential offered by mTOR inhibitors toward the treatment of various types of cancers such as lung cancer, breast cancer, and colorectal cancer, among others, is one of the key factors expected to drive the global mTOR inhibitors market during the assessment period. P13K signaling pathway are expected to play a key role in cell growth, survival, and proliferation due to which, the demand for P13K inhibitors as an anticancer therapy has increased at a rapid pace.
In recent years, the promising outcome of preclinical studies using rapamycin and its derivatives have resulted in the surge of a numerous clinical trials that aim to assess the effectiveness of mTOR inhibitor therapies– a factor that is likely to boost the prospects of the global mTOR inhibitors market during the forecast period.
The outbreak of the novel COVID-19 pandemic is expected to have a short-term impact on the growth of the global mTOR inhibitors market in 2020. While research and development activities are expected to go on in full swing, market players are increasingly exploring the potential of mTOR inhibitors as an alternative COVID-19 therapy. Due to unclear outcomes from clinical trials and early stages of research, the adoption of mTOR dependent pathways, as COVID-19 therapy is anticipated to remain sluggish. However, market growth is projected to gain momentum toward the last quarter of 2020 and the first quarter of 2021. The increasing prevalence of cancer is likely to play a key role in the overall development of the global mTOR inhibitors market during the forecast period.